This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
After-Hours Selling to Challenge Winning Streak Wednesday
by Mark Vickery
Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Await Consumer Credit Report
by Zacks Equity Research
Markets Await Consumer Credit Report
Can Markets Keep the Winning Streak Intact?
by Mark Vickery
Uber missed on headline although business was good, D.R. Horton beat and raised, and the U.S. trade deficit got slimmer.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
by Zacks Equity Research
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.
3 Biotech Stocks With Decent Dividend for a Steady Return
by Indrajit Bandyopadhyay
Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.
GILD or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. VRTX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger
by Zacks Equity Research
Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Q3 Earnings Scorecard and Analyst Reports for Walmart, Nike & TJX
by Sheraz Mian
Today's Research Daily features a real-time scorecard of the Q3 earnings season and new research reports on 16 stocks, including Walmart, Nike & TJX.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.
Nurix (NRIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
by Zacks Equity Research
The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.